Floatz logo

ROCK2 INHIBITOR KD025

Plasma Cell Myeloma Refractory

SanofiSmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

497 Active assets in the Plasma Cell Myeloma Refractory cohort.

Asset / SponsorPhaseRating
FILGRASTIM
Jonsson Comprehensive Cancer Center
Phase 4BBB
Busulphan
M.D. Anderson Cancer Center
Phase 4BBB
Hyaluronidase fihj
Massachusetts General Hospital
Phase 4BBB
Inno-206
University of Arkansas
Phase 3BBB
Filanesib
PETHEMA Foundation
Phase 2BBB

View all 50 →

Same molecule, other indications

ROCK2 INHIBITOR KD025 is also rated in:

idiopathic pulmonary fibrosisDormant
CCC
Indicative ·
54 / 100
View asset →
plasma cell myelomaDormant
CC
Indicative ·
40 / 100
View asset →
colorectal cancerDormant
C
Indicative ·
38 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →